Dr. Richard Pazdur, director of FDA's Office of Hematology and Oncology Products, tells BioCentury why the FDA is racing to approve new cancer drugs. Dr. Pazdur says new targeted drugs and immunotherapies with unprecedented efficacy are the payoff from 20 years of basic science. He calls for greater patient engagement in drug development, says compassionate access should be improved, and predicts rapid uptake of biosimilars. (4/21/15)

Latest Videos

Putnam investments
Nick Thakore and Bob Ewing, co-heads of U.S. equities, discuss small- and large-cap stock performance in the biotech sector.
4/29/15
Biotech Offers Opportunity
Fortune Magazine
A Boston-area biotech firm could be closing in on a possible cure for Alzheimer's. Fortune magazine profiles Biogen in its latest issue, and Leigh Gallagher joins Morning Joe to discuss why the firm may be closing in on a cure.
4/23/15
Solving the Alzheimer's Puzzle
DNA strand
Today's video highlights include AstraZeneca, Onglyza, Kombiglyze, Takeda, Nesina, FDA, Pfizer, Ibrance, tremelimumab, Merck & Co., NewLink Genetics and rVSV-ZEBOV.
4/15/15
This Week in Pharma
The Street
Biotech valuations may be relatively high in some cases, but on the whole they are not overly stretched and certainly not in bubble territory, said Marshall Gordon, Senior Research Analyst at ClearBridge Investments.
4/6/15
Biotech Rally Not Over
Fierce Biotech
FierceBiotech Editor-in-Chief John Carroll sits down with Bloomberg Intelligence analyst Asthika Goonewardene to discuss biotech's big year and whether it's sustainable.
3/23/15
Is this a Biotech Bubble?
bleeding money
A look at the NASDAQ Biotech index. Is there a bubble? Austrian Markets looks at the data.
3/22/15
The Bleeding Biotechs
lab outfit
At the University of Pennsylvania, a research team has been working on an experimental treatment to kill leukemia with a patient's own immune system cells. So far, the results have shown startling success. Special correspondent Jackie Judd reports on the growing research on immunotherapy in fighting cancer.
3/17/15
Cells on the Hunt
Daniel Shedivy
William Blair Managing Director Daniel Shedivy talks about what the upsurge in M&A means for the healthcare sector.
3/13/15
M&A Deals Surge
chart
Healthcare analyst Michael Douglass and healthcare contributor Todd Campbell discuss the pitfalls and potential of two small-cap biotech stocks.
3/5/15
Tiny Bios, Big Opportunity
DNA strand
Today's video highlights include Takeda, Bristol-Myers Squibb, Bavarian Nordic, Prostvac, Yervoy, Orexigen Therapeutics, Contrave, FDA, Pfizer, Prevenar 13 and the European Commission.
3/4/15
Pharma and Biotech Round-Up
blue petri
Analysts Michael Douglass and Todd Campbell discuss two small biotechs that recently reported hepatitis C data and look at their opportunity in this large and competitive market.
2/12/15
Biotechs Dream Big
Biotech NASDAQ
BIO Buzz Center with Nelson Griggs , Executive Vice President of Global Listing Services of NASDAQ at the 2015 BIO CEO & Investor Conference.
2/12/15
Transforming Fundraising